Literature DB >> 27224019

Intra-amygdala microinfusion of neuropeptide S attenuates neuropathic pain and suppresses the response of spinal microglia and astrocytes after spinal nerve ligation in rats.

Fengrui Yang1, Liangyu Peng1, Jingjing Luo1, Han Yi1, Xiaoling Hu2.   

Abstract

The amygdala circuitry and neuropeptide S (NPS) have been shown to play an important role in the pain modulation. However, the alleviative effect of NPS in amygdala on neuropathic pain (NP) is not fully understood. Here, we demonstrate a possibility that the intra-amygdala microinfusion of NPS attenuates NP symptoms and suppresses the response of spinal microglia and astrocytes after spinal nerve injury. Spinal nerve ligation (SNL) in rats resulted in a striking decline in level of NPS and density of NPS-immunopositive cells in amygdala. SNL rats randomly received chronic bilateral microinjections of NPS (1, 10 and 100pmol/side) or saline into the amygdala via cannulas on days 3, 6, 9, 12, 15 and 18 post-surgery. Chronic treatment with NPS increased thermal withdrawal latency (TWL) and mechanical withdrawal threshold (MWT) on day 11-21 post-SNL. The simultaneous treatment with SHA68 as non-peptide NPS receptor antagonist decreased the TWL and MWT, and reversed the inhibitory effects of NPS in SNL rats. NPS also significantly attenuated immunoreactivities of ionized calcium-binding adapter molecule 1 and glial fibrillary acidic protein for microglia and astrocytes. Furthermore, the elevated levels of inflammatory mediators and expressions of nuclear factor κB p65 and CX3C chemokine receptor 1 due to SNL were significantly attenuated by NPS in amygdala. These effects of NPS were also counteracted by SHA 68. SHA 68 per se deteriorated the symptom of NP and the response of spinal microglia and astrocytes in SNL rats. Our study identified a protective role for NPS in amygdala against the development of NP, possibly attributing to its anti-inflammatory activity and inhibition of spinal microglia and astrocytes.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Amygdala; Astrocytes; Microglia; Neuropathic pain; Neuropeptide S; Neuropeptide S receptor

Mesh:

Substances:

Year:  2016        PMID: 27224019     DOI: 10.1016/j.peptides.2016.05.005

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  5 in total

1.  Central noradrenergic activity affects analgesic effect of Neuropeptide S.

Authors:  Kei Jinushi; Tetsuya Kushikata; Takashi Kudo; Girolamo Calo; Remo Guerrini; Kazuyoshi Hirota
Journal:  J Anesth       Date:  2017-11-11       Impact factor: 2.078

2.  Relationship of Neuropeptide S with Clinical and Metabolic Parameters of Patients during Rehabilitation Therapy for Schizophrenia.

Authors:  Agnieszka Markiewicz-Gospodarek; Renata Markiewicz; Beata Dobrowolska; Ryszard Maciejewski; Bartosz Łoza
Journal:  Brain Sci       Date:  2022-06-11

Review 3.  Amygdala, neuropeptides, and chronic pain-related affective behaviors.

Authors:  Volker Neugebauer; Mariacristina Mazzitelli; Bryce Cragg; Guangchen Ji; Edita Navratilova; Frank Porreca
Journal:  Neuropharmacology       Date:  2020-03-15       Impact factor: 5.250

4.  The role of miR-190a-5p contributes to diabetic neuropathic pain via targeting SLC17A6.

Authors:  Di Yang; Qinyan Yang; Xinchuan Wei; Yang Liu; Ding Ma; Jiaceng Li; Yongling Wan; Yao Luo
Journal:  J Pain Res       Date:  2017-10-04       Impact factor: 3.133

Review 5.  Roles of Neuropeptide S in Anesthesia, Analgesia, and Sleep.

Authors:  Tetsuya Kushikata; Kazuyoshi Hirota; Junichi Saito; Daiki Takekawa
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.